A Study of ZD1839 effects on cell proliferation in Breast cancer

Study identifier:1839IL/0509

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery

Medical condition

Breast Cancer

Phase

Phase 2

Healthy volunteers

Study drug

Gefitinib

Sex

Female

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2004

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Information

+39 02 98011

Investigators

Principal Investigator

AstraZeneca Italy Medical Director

AstraZeneca